Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) Gross Margin (2016 - 2025)

Medifast's Gross Margin history spans 16 years, with the latest figure at 69.43% for Q4 2025.

  • For Q4 2025, Gross Margin fell 470.0% year-over-year to 69.43%; the TTM value through Dec 2025 reached 71.33%, down 247.0%, while the annual FY2025 figure was 71.33%, 247.0% down from the prior year.
  • Gross Margin reached 69.43% in Q4 2025 per MED's latest filing, roughly flat from 69.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 75.39% in Q3 2024 to a low of 69.27% in Q4 2022.
  • Average Gross Margin over 5 years is 72.57%, with a median of 72.82% recorded in 2024.
  • Peak YoY movement for Gross Margin: skyrocketed 474bps in 2023, then plummeted -587bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 73.65% in 2021, then decreased by -6bps to 69.27% in 2022, then grew by 7bps to 74.01% in 2023, then grew by 0bps to 74.13% in 2024, then dropped by -6bps to 69.43% in 2025.
  • Per Business Quant, the three most recent readings for MED's Gross Margin are 69.43% (Q4 2025), 69.52% (Q3 2025), and 72.61% (Q2 2025).